New Eli Lilly drug comes up short in liver cancer trial

June 11, 2014 3:48 PM

4 0

New Eli Lilly drug comes up short in liver cancer trial

A study on patients with advanced liver cancer using Eli Lilly and Co.’s new cancer drug Cyramza failed to meet its primary goal of overall patient survival.

The Indianapolis drug maker said today that the late-phase trial showed that the drug didn’t result in statistically significant survival rates for patients when compared to placebo and best supportive care. All patients in the blinded trial had previously been treated with another cancer drug, whic...

Read more

To category page

Loading...